Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

Open access

Abstract

BACKGROUND: The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those proteasome inhibitors indicate the need for a new generation of drugs. Therefore, we focused on developing an oral proteasome inhibitor with improved efficacy and safety profiles. METHOD: The in vitro inhibition of the 20S proteasome catalytic activities was determined in human multiple myeloma (MM) cellular lysates with fluorogenic peptide substrates specific for each catalytic subunit. Cell cytotoxicity was assessed with the ATP bioluminescence assay using human cell samples from tumor cell lines, MM patients or normal healthy donors. In mice bearing human MM xenografts, a single dose of LC53-0110 was administered orally, and concentration-time profiles of LC53-0110 and the 20S proteasome catalytic activities in plasma, blood, and tumor were determined. The efficacy of repeat-dose compound with regard to tumor growth inhibition in vivo was also evaluated in the same MM xenograft models. RESULTS: LC53-0110 is far more specific for the chymotrypsin-like proteolytic (β5) site of the 20S proteasome as compared to bortezomib, carfilzomib, or ixazomib. LC53-0110 treatment showed accumulation of ubiquitinated proteins, inhibited cell viability with a low nM range potency in various tumor cell lines, and showed potent activity on CD138(+) cells isolated from MM patients who are resistant/refractory to current FDA-approved drug treatment. When a single dose was administered orally to tumor-bearing mice, LC53-0110 showed both greater maximum and sustained tumor proteasome inhibition as compared with ixazomib in MM xenograft models. The robust pharmacodynamic responses in tumor correlated with tumor growth regression. In addition, LC53-0151, an analog of LC53-0110, in combination with pomalidomide, a third-generation immunomodulatory drug, showed synergistic inhibition of tumor growth both in vitro and in the xenograft mouse model. CONCLUSIONS: In view of the in vitro, in vivo, and ex vivo profiles, further investigation of additional LC compounds in preclinical studies is warranted for the nomination of a clinical development candidate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-016-2285-2

Cites

Statistics

Figures

Fig. 1 Inhibition of non-proteasomal proteases. 10 μM of proteasome inhibitor compounds were tested with a panel of proteases, Cathepsin G (serine protease with P1 specificity of phenylalanine/leucine/tyrosine), Elastase (neutrophil serine protease with P1 specificity of valine), Cathepsin B (cysteine protease), Renin (aspartate protease), and ACE (metalloprotease angiotensin converting enzyme). Percent inhibition was calculated based on compound’s effect on protease activity subtracted with a substrate control without an enzyme
Fig. 1 Inhibition of non-proteasomal proteases. 10 μM of proteasome inhibitor compounds were tested with a panel of proteases, Cathepsin G (serine protease with P1 specificity of phenylalanine/leucine/tyrosine), Elastase (neutrophil serine protease with P1 specificity of valine), Cathepsin B (cysteine protease), Renin (aspartate protease), and ACE (metalloprotease angiotensin converting enzyme). Percent inhibition was calculated based on compound’s effect on protease activity subtracted with a substrate control without an enzymeCC BY · PubMed Central
Fig. 2 Accumulation of ubiquitinated proteins and activation of apoptosis in cells. Lysates were prepared from RPMI8226 cells 4 h (a) or 24 h (b, c, d) after a 1-h treatment with 0.1 % DMSO or 500 nM of proteasome inhibitors. Western blot analysis was done with anti-Ubiquitin, anti-p21, anti-β-Catenin, anti-Hsp70, anti-phospho Hsp27 (S82), anti-Hsp27, anti-Gadd34, anti-caspase-8, and anti-caspase-9 antibodies. α-Tubulin was used as a loading control. Cleaved caspase-8 and 9 bands on the western blot were quantitated and expressed as a fold-increase over DMSO control
Fig. 2 Accumulation of ubiquitinated proteins and activation of apoptosis in cells. Lysates were prepared from RPMI8226 cells 4 h (a) or 24 h (b, c, d) after a 1-h treatment with 0.1 % DMSO or 500 nM of proteasome inhibitors. Western blot analysis was done with anti-Ubiquitin, anti-p21, anti-β-Catenin, anti-Hsp70, anti-phospho Hsp27 (S82), anti-Hsp27, anti-Gadd34, anti-caspase-8, and anti-caspase-9 antibodies. α-Tubulin was used as a loading control. Cleaved caspase-8 and 9 bands on the western blot were quantitated and expressed as a fold-increase over DMSO controlCC BY · PubMed Central
Fig. 3 Inhibition of cellular viability in patient-derived samples. a CD138+ cells were purified from the bone marrow samples of MM patients (3, 4, 6–8, 11, 14–16). The cytotoxic effects of LC53-0110 (filled rectangle) and ixazomib (open circle) were determined by bioluminescent measurement of cellular ATP using CellTiter-Glo reagent after 48 h of treatment. Results are expressed as % cell viability over DMSO control. b The IC50 values for LC53-0110 treated MM patients
Fig. 3 Inhibition of cellular viability in patient-derived samples. a CD138+ cells were purified from the bone marrow samples of MM patients (3, 4, 6–8, 11, 14–16). The cytotoxic effects of LC53-0110 (filled rectangle) and ixazomib (open circle) were determined by bioluminescent measurement of cellular ATP using CellTiter-Glo reagent after 48 h of treatment. Results are expressed as % cell viability over DMSO control. b The IC50 values for LC53-0110 treated MM patientsCC BY · PubMed Central
Fig. 4 PD and PK profiles of LC53-0110 in mice bearing human multiple myeloma xenografts. a MM.1S tumor bearing mice were administered orally with a single dose of LC53-0110 at 50 mg/kg, and the 20S proteasome catalytic activities in tumor and blood were evaluated with CT-L subunit-specific fluorogenic peptide substrates. Data points, mean +/−SE (n = 3). b In the same study, concentration-time profiles of LC53-0110 in plasma, blood, and tumor were determined. Data points, mean +/−SD (n = 3)
Fig. 4 PD and PK profiles of LC53-0110 in mice bearing human multiple myeloma xenografts. a MM.1S tumor bearing mice were administered orally with a single dose of LC53-0110 at 50 mg/kg, and the 20S proteasome catalytic activities in tumor and blood were evaluated with CT-L subunit-specific fluorogenic peptide substrates. Data points, mean +/−SE (n = 3). b In the same study, concentration-time profiles of LC53-0110 in plasma, blood, and tumor were determined. Data points, mean +/−SD (n = 3)CC BY · PubMed Central
Fig. 5 Anti-tumor activity of LC53-0110 in mice bearing human multiple myeloma xenografts. a The LC and reference compounds were orally administered twice a week (BIW) or once a week (QW) in mice bearing MM.1S xenografts as indicated. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. Data points, mean+/−SE (n = 6). b LC53-0110 was orally administered twice a week or once a week in mice bearing RPMI8226 xenografts as indicated, and reference compounds were intravenously administered twice a week. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. Data points, mean+/−SE (n = 8)
Fig. 5 Anti-tumor activity of LC53-0110 in mice bearing human multiple myeloma xenografts. a The LC and reference compounds were orally administered twice a week (BIW) or once a week (QW) in mice bearing MM.1S xenografts as indicated. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. Data points, mean+/−SE (n = 6). b LC53-0110 was orally administered twice a week or once a week in mice bearing RPMI8226 xenografts as indicated, and reference compounds were intravenously administered twice a week. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. Data points, mean+/−SE (n = 8)CC BY · PubMed Central
Fig. 6 Anti-tumor activity of an LC53-0110 analog combined with an immunomodulatory drug. a The cytotoxic effects of 5 nM of LC53-0151 or 2 μM of pomalidomide alone or together on MM.1S cells were determined by MTT assay. b LC53-0151 or pomalidomide alone or together in mice bearing MM.1S xenografts as indicated. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. c The mean tumor weight for each animal in the vehicle and treatment groups was determined at the end of the study. Data points, mean+/−SE (n = 8)
Fig. 6 Anti-tumor activity of an LC53-0110 analog combined with an immunomodulatory drug. a The cytotoxic effects of 5 nM of LC53-0151 or 2 μM of pomalidomide alone or together on MM.1S cells were determined by MTT assay. b LC53-0151 or pomalidomide alone or together in mice bearing MM.1S xenografts as indicated. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. c The mean tumor weight for each animal in the vehicle and treatment groups was determined at the end of the study. Data points, mean+/−SE (n = 8)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 55 · Cited by 9

Metadata

Authors
Park, J., Park, E., Jung, C.-K., Kang, S.-W., Kim, B. G., Jung, Y., Kim, T. H., Lim, J.-Y., Lee, S.-E., Min, C.-K., & Won, K.-A.
Affiliations
  • LG (South Korea) (KR)
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
Corresponding author
Won, Kwang-Ai
Venue
BMC Cancer
Published
2016-03-24
Volume
16
Issue
1
Pages
247-247
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2310758743
Cited by
9
References
55
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2018: 1 · 2017: 1
FWCI
0.35
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Seoul St. Mary's Hospital, Catholic University of Korea
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
oral proteasome inhibitor, multiple myeloma, 20S proteasome, proteasome inhibition, CD138+ cells, drug resistance, refractory multiple myeloma, pharmacodynamics, tumor xenografts, ubiquitinated proteins
MeSH terms
Bortezomib, Aged, Animals, Antineoplastic Agents, Boron Compounds, Cell Survival, Drug Synergism, Female, Glycine, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Thalidomide, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proteasome Endopeptidase Complex, Cell Proliferation, Mice, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. https://app.cochat.ai/papers/10.1186/s12885-016-2285-2
The paper
Park, J., Park, E., Jung, C.-K., Kang, S.-W., Kim, B. G., Jung, Y., Kim, T. H., Lim, J.-Y., Lee, S.-E., Min, C.-K., & Won, K.-A. (2016). Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer. https://doi.org/10.1186/s12885-016-2285-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.